Duvelisib was the second PI3K inhibitor approved with the FDA, also depending on a section III randomized demo.130 The efficacy and security profile of your drug look equivalent with those of idelalisib, if not a bit useful. Relating to different BTK inhibitors, there are lots of items in development, but only acalabrutinib is accredited by the FDA